Reid Hoffman is leaving Microsoft’s board to go ‘founder mode’ with startup Manus
After a very profitable decade on Microsoft's board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus.
After a very profitable decade on Microsoft's board, Reid Hoffman is stepping down to focus on his AI drug discovery startup Manus. This report comes
Read Full Story at TechCrunch →Why This Matters
Reid Hoffman’s departure from Microsoft’s board signals a broader shift in Silicon Valley’s elite, where founder-entrepreneurs are reclaiming control over their most ambitious ventures. His pivot to Manus, an AI-driven drug discovery firm, underscores the growing intersection between big tech’s legacy players and high-stakes biotech innovation.
Background Context
Hoffman’s decade-long tenure on Microsoft’s board coincided with the company’s resurgence under Satya Nadella, where his strategic acumen and venture capital ties helped shape the tech giant’s AI and cloud ambitions. Manus, meanwhile, represents a high-risk bet on AI’s potential to revolutionize pharmaceutical R&D—a space increasingly crowded by both startups and Big Pharma.
What Happens Next
Hoffman’s exit could pressure other tech luminaries to prioritize founder-led projects over boardroom roles, potentially reshaping corporate governance in Silicon Valley. For Manus, the challenge will be translating AI hype into tangible drug discoveries while competing with deep-pocketed rivals like BenevolentAI and Recursion.
Bigger Picture
This move reflects a wider trend of ex-CEOs and tech titans returning to founder mode, leveraging their networks and capital to disrupt industries beyond software. It also highlights the arms race in AI-driven biotech, where the same algorithms fueling chatbots are now being repurposed to crack one of science’s hardest problems.
